Brian Park, PharmD

Drug Information Specialist https://www.dermatologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Acne, News, Uncategorized

Minocycline Foam Safe, Effective for Acne, According to Long-Term Trial Data

Brian Park, PharmD

November 8, 2019

Minocycline foam 4% (Amzeeq; Foamix) appears to be safe and effective for moderate-to- severe acne, according to findings from a long-term, open-label safety study.

Practice Management

New Report Identifies Causes, Potential Solutions for Drug Shortages

Brian Park, PharmD

November 5, 2019

The FDA has issued a report assembled by the inter-agency Drug Shortages Task Force to determine the root causes of drug shortages, and to offer recommendations based on the insights from stakeholders in the private and public sectors to help prevent future drug shortages.

Psoriasis

Guselkumab Demonstrates Lasting Benefits in Plaque Psoriasis Patients, According to 4-Year Data

Brian Park, PharmD

October 24, 2019

Results found that 82% of patients in the combined group achieved PASI 90 and IGA 0/1 at week 204.

Psoriasis

Bimekizumab Compared With Ustekinumab in Plaque Psoriasis Trial

Brian Park, PharmD

October 23, 2019

Bimekizumab met both co-primary end points as well as key secondary end points demonstrating superior to ustekinumab and placebo at Week 16.

Practice Management

FDA: Cybersecurity Vulnerabilities Identified With Certain Medical Devices, Hospital Networks

Brian Park, PharmD

October 8, 2019

The URGENT/11 vulnerabilities exist in a third-party software, called IPnet.

Dermatitis

Abrocitinib Effective in Second Phase 3 Atopic Dermatitis Trial

Brian Park, PharmD

October 3, 2019

Pfizer announced positive topline results from the phase 3 JADE MONO-2 trial of abrocitinib, an oral Janus kinase 1 inhibitor, for the treatment of moderate to severe atopic dermatitis.

General Dermatology

Nomacopan Receives Orphan Drug Designation for Bullous Pemphigoid

Brian Park, PharmD

September 18, 2019

The Company is currently evaluating nomacopan in an ongoing phase 2 trial in patients with bullous pemphigoid.

Next post in General Dermatology